Preclinical assessment of iodantipyrine safety

A. S. Saratikov, T. P. Novozheeva, N. S. Livshits, F. I. Burchenkova, N. G. Kadychagova, R. R. Akhmedzhanov, L. V. Bashirova, A. A. Eremina, G. V. Potapova

Research output: Contribution to journalArticle

Abstract

Detailed preclinical study of the safety of the new antiviral agent iodantipyrine was conducted. In LD50 parameters it was found to be related to moderately toxic drugs. Long-term administration in doses of 50, 100, and 250 mg/kg did not cause any essential functional and structural disorders in the organs and systems of rats and dogs. Iodantipyrine does not possess mutagenic and allergenic properties and does not affect the reproductive function.

Original languageEnglish
Number of pages1
JournalEksperimental'naya i Klinicheskaya Farmakologiya
Volume61
Issue number2
Publication statusPublished - 1 Jan 1998

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Fingerprint Dive into the research topics of 'Preclinical assessment of iodantipyrine safety'. Together they form a unique fingerprint.

  • Cite this

    Saratikov, A. S., Novozheeva, T. P., Livshits, N. S., Burchenkova, F. I., Kadychagova, N. G., Akhmedzhanov, R. R., Bashirova, L. V., Eremina, A. A., & Potapova, G. V. (1998). Preclinical assessment of iodantipyrine safety. Eksperimental'naya i Klinicheskaya Farmakologiya, 61(2).